Sanofi is still set on taking its multiple sclerosis (MS) med tolebrutinib to the FDA, executives have told Fierce Biotech, ...
Let's dive into a conversation with Ayla Ellison, Fierce Biotech Editor-in-Chief and Michelle Benz as they discuss the ...
New data reveal how Bayer's asundexian failed to prevent strokes, imperiling $5.5B blockbuster hopes
The full picture of how Bayer's factor XIa inhibitor asundexian showed "inferior efficacy" compared to Eliquis has come into ...
A study from Abbott found that employing its cardiac valve repair implant during earlier phases of heart failure—when a ...
Shanghai Allist Pharmaceuticals has bought itself a starring role in China’s KRAS market, paying Jacobio Pharma 150 million ...
The FDA has approved a new type of stent designed specifically for infants and young children—including neonates born with ...
The FDA’s Center for Drug Evaluation and Research (CDER) is consolidating its artificial-intelligence-related activities ...
Illumina has secured an FDA approval to bring its pan-cancer tissue profiling test to U.S. shores. | The TruSight Oncology ...
ReNeuron has joined the long list of biotechs to leave London’s AIM stock market. | ReNeuron has joined the long list of ...
The Roche subsidiary will lay off 93 employees in South San Francisco starting in early October, according to a Worker ...
Medtech startups fared well in the second quarter with investment activity on track to surpass last year and ventu | ...
Earlier this month, Lykos was hit by an FDA rejection, research paper retractions and layoffs. Now, the FDA is looking into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results